Key result
Remote telemonitoring cuts 45-day admissions or ER visits ~25% vs usual care.
Why the study?
The efficacy of telemonitoring in patients with advanced heart and lung failure was unknown.
Does a remote bio-parameters telemonitoring system reduce admissions and emergency room visits in patients with advanced heart and lung failure?
RCT (n=510)
Randomized
Yes
Does a remote bio-parameters telemonitoring system reduce admissions and emergency room visits in patients with advanced heart and lung failure?
Absolute Event Rate: 35.4% vs 46.9%
p-value: p=< 0.05
Adding a telemonitoring system to integrated care for patients with advanced heart and lung failure significantly reduces hospital and emergency admissions while improving quality of life and being cost-effective.
Supports telemonitoring integration into advanced heart and lung failure care; extends RCT evidence to mixed cardiopulmonary populations.
Brief Summary The addition of home monitoring to an integrated care model in patients with advanced chronic heart/lung diseases decreases mortality, hospital and emergency admissions, improves functional status, HRQoL, and is cost-effective. Background Telemonitoring is a promising implement for medicine, but its efficacy is unknown in patients with advanced heart and lung failure (AHLF). Objective To determine the efficacy of a telemonitoring system added to coordinated clinical care in patients with AHLF. Design Randomized phase 3 multicenter clinical trial with parallel groups in adult patients. Participants Five spanish centers including patients with AHLF at discharge or in out-patient clinics. Intervention Patients were randomly assigned to receive a remote bio-parameters telemonitoring system (TELECARE) or best usual care (UCARE). TELECARE patients were provided with devices that collected symptoms and bio-parameters, and transferred them synchronously to a call-center, with a real-time health-care response. Main Measures Primary end point was the need of admissions/emergency room visits at 45, 90, 180 days. Secondary end points included health care requirements, mortality, functional assessment, health related quality of life (HRQoL), perceived satisfaction, and cost-efficacy. Results 510 patients were included (54.5% women, median age 76.5 years; 63.1% suffered heart failure, 13.9% lung failure, and 22.9% both conditions). Clinical and functional features were comparable in both arms. TELECARE globally needed less admissions with respect UCARE after 45 days of inclusion (35.4% vs. 46.9%, p < 0.05). This tendency was maintained in the subgroups of patients with multimorbidity (34.2% vs. 46.9%, p < 0.05), intermediate risk of mortality (36.5% vs. 51.1%, p < 0.05), and those included after hospital discharge (34.9% vs. 50.5%, p < 0.01). HRQoL significantly improved (TELECARE/UCARE EuroQol baseline of 56.2 ± 18.2/55.1 ± 19.7, p = 0.054, and 64 ± 19.9/56.3 ± 21.6; p < 0.01 at the end), and perceived satisfaction was also higher (6.77 ± 0.52 vs. 6.62 ± 0.81, p < 0.001; highest possible score = 7). A trend to mortality decrease was also observed (12.9% vs. 19.3%, p = 0.13). TELECARE was cost-efficacious (TELECARE/UCARE QALY 3.94 Euros/0.81Euros). Conclusions The addition of a telemonitoring system to an integrated care model in patients with AHLF decreases hospital and emergency admissions, improves functional status as well as HRQoL, and is cost-efficacious.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted an RCT in Advanced heart and lung failure (AHLF) (n=510). Remote bio-parameters telemonitoring system (TELECARE) vs. Best usual care (UCARE) was evaluated on Need of admissions/emergency room visits at 45, 90, 180 days (p=< 0.05). Remote telemonitoring reduced the need for admissions or emergency room visits at 45 days compared to usual care in patients with advanced heart and lung failure (35.4% vs 46.9%; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: